# EDGAR Filing Document

**Accession Number:** 0001808865
**File Stem:** 0000950170-23-000424
**Filing Date:** 2023-1
**Character Count:** 27450
**Document Hash:** df32ef88db58b9510449a190453ec6b8
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000950170-23-000424.hdr.sgml**: 20230109

**ACCESSION NUMBER**: 0000950170-23-000424

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 32

**CONFORMED PERIOD OF REPORT**: 20230109

**ITEM INFORMATION**: Regulation FD Disclosure

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20230109

**DATE AS OF CHANGE**: 20230109

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** iTeos Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001808865
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **IRS NUMBER:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39401
- **FILM NUMBER:** 23516500

**BUSINESS ADDRESS:**
- **STREET 1:** 321 ARSENAL STREET
- **STREET 2:** BLDG 312, FLOOR 3, SUITE 301
- **CITY:** WATERTOWN
- **STATE:** MA
- **ZIP:** 02472
- **BUSINESS PHONE:** 857-204-4583

**MAIL ADDRESS:**
- **STREET 1:** 321 ARSENAL STREET
- **STREET 2:** BLDG 312, FLOOR 3, SUITE 301
- **CITY:** WATERTOWN
- **STATE:** MA
- **ZIP:** 02472

?xml version="1.0" encoding="ASCII"? 8-K

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549**

------

**FORM** 8-K

------

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported):** January 09, 2023<br>

------

iTeos Therapeutics, Inc.

**(Exact name of Registrant as Specified in Its Charter)**

------

---

| | | |
|:---|:---|:---|
| Delaware | 001-39401 | 84-3365066 |
| **(State or Other Jurisdiction<br>of Incorporation)** | **(Commission File Number)** | **(IRS Employer<br>Identification No.)** |
| 321 Arsenal Street  |  |  |
| Watertown **,** Massachusetts |  | 02472 |
| **(Address of Principal Executive Offices)** |  | **(Zip Code)** |

---

**Registrant's Telephone Number, Including Area Code:** 339 217 0161<br>

**(Former Name or Former Address, if Changed Since Last Report)**

------

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Securities registered pursuant to Section 12(b) of the Act:**

---

| | | |
|:---|:---|:---|
| **<br>Title of each class** | **Trading<br>Symbol(s)** | **<br>Name of each exchange on which registered** |
| Common Stock, $0.001 par value per share | ITOS | The NASDAQ Global Market |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

**Item 7.01 Regulation FD Disclosure.**

On January 10, 2023, Michel Detheux, Ph.D., President and Chief Executive Officer of iTeos Therapeutics, Inc., will present at the 41st Annual J.P. Morgan Healthcare Conference (the "<u>Conference</u>"). The slides that will be presented by Dr. Detheux at the Conference are furnished with this report as Exhibit 99.1, which is incorporated herein by reference.

The information in this Item 7.01 is furnished pursuant to Item 7.01 and shall not be deemed "filed" for the purposes of Section 18 of the Securities and Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section. It may only be incorporated by reference in another filing under the Exchange Act or the Securities Act of 1933, as amended, if such subsequent filing specifically references the information furnished pursuant to Item 7.01 of this report.

**Item 9.01 Financial Statements and Exhibits.**

---

| | |
|:---|:---|
| <u>Exhibit No.</u> | <u>Description</u> |
| 99.1 | [<u>iTeos Therapeutics, Inc. Presentation at the 41st Annual J.P. Morgan Healthcare Conference dated January 10, 2023</u>](itos-ex99_1.htm) |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |

---

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

---

| | | | |
|:---|:---|:---|:---|
|  |  |  | iTeos Therapeutics, Inc.  |
| Date: | January 9, 2023 | By:  | /s/ Michel Detheux  |
|  |  |  | Michel Detheux, Ph.D.<br>President and Chief Executive Officer  |

---

------

## Exhibit 99.1

![Slide 1](itos-ex99_1s1.jpg)

Better Immunotherapiesto Improve the Lives of People with Cancer Nasdaq: ITOS January 2023

------

![Slide 2](itos-ex99_1s2.jpg)

Forward-Looking Statements This presentation contains forward-looking statements. Any statements that are not solely statements of historical fact are forward-looking statements. Words such as "believe," "anticipate," "plan," "expect," "will," "may," "intend," "prepare," "look," "potential," "possible" and similar expressions are intended to identify forward-looking statements. These forward-looking statements include statements relating to the potential benefits of our product candidates and combinations; the potential of TIGIT to be the next advance in cancer treatment; the potential of our biomarker to guide patient selection; our clinical plans and expected timelines, including the expectation to make significant progress in 2023 and that EOS-984 will enter into the clinic in mid-2023; our potential market opportunities; the potential benefits of our collaboration with GSK, including dostarlimab being the ideal combination partner for EOS-448; the potential to differentiate EOS-448 to win with the quality of our therapies, major indications and unique combinations; the expectation that 2023 will be a pivotal year for TIGIT and iTeos being ideally positioned to enter this year; and our expected cash runway into 2026. These forward-looking statements involve risks and uncertainties, many of which are beyond iTeos' control. Actual results could materially differ from those stated or implied by these forward-looking statements as a result of such risks and uncertainties. Known risk factors include the following: success in preclinical testing and early clinical trials does not ensure that later clinical trials will be successful, and early results from a clinical trial do not necessarily predict final results; the data for our product candidates may not be sufficient to support regulatory approval; iTeos may encounter unanticipated costs or may expend cash more rapidly or more slowly than currently anticipated due to challenges and uncertainties inherent in product research and development and biologics manufacturing; the expected benefits and opportunities related to the agreement between iTeos and GSK may not be realized or may take longer to realize than expected due to a variety of reasons, including any inability of the parties to perform their commitments and obligations under the agreement, challenges and uncertainties inherent in product research and development and manufacturing limitations; iTeos may not be able to execute on its business plans, including meeting its expected or planned regulatory milestones and timelines, research and clinical development plans, and bringing its product candidates to market, for various reasons, some of which may be outside of iTeos' control, including possible limitations of company financial and other resources, manufacturing limitations that may not be anticipated or resolved for in a timely manner, regulatory, court or agency decisions such as decisions by the United States Patent and Trademark Office with respect to patents that cover our product candidates and the impact of the COVID-19 pandemic; and those risks identified under the heading "Risk Factors" in iTeos' Quarterly Report on Form 10-Q for the nine months ended September 30, 2022 filed with the Securities and Exchange Commission (SEC) as well as other SEC filings made by the Company which you are encouraged to review. Statements regarding the Company's cash runway do not indicate when the Company may access the capital markets. Statements regarding the Company's cash runway do not indicate when the Company may access the capital markets. Any of the foregoing risks could materially and adversely affect iTeos' business, results of operations and the trading price of iTeos' common stock. We caution investors not to place considerable reliance on the forward-looking statements contained in this press release. iTeos does not undertake any obligation to publicly update its forward-looking statements based on events or circumstances after the date hereof. 2

------

![Slide 3](itos-ex99_1s3.jpg)

Better Immunotherapiesto Improve the Lives of People with Cancer Nasdaq: ITOS January 2023

------

![Slide 4](itos-ex99_1s4.jpg)

iTeos well positioned to deliver better drugs to patients Cash balance to fund development into 2026 752 Clinical studies planned or ongoing 68 Patients diagnosed each year in US for indications currently in development 3 Clinical drug candidates in 2023 Years of expertise in tumor immunology Partnership with unique development possibilities 4 1 0 1 1 K M\* $2 B $\* As of September 30, 2022

------

![Slide 5](itos-ex99_1s5.jpg)

We build better drugs for people with cancer EOS-448: Anti-TIGIT optimized for immune cell activation Inupadenant & EOS-984: Designed to fully exploit the adenosine pathway Expansive and unique development plan with GSK Leverage deep understanding of the adenosine pathway with a focused clinical plan

------

![Slide 6](itos-ex99_1s6.jpg)

Discovery Preclinical Phase 1 Phase 2 Phase 3 Expansive and differentiated development pipeline expected to make significant progress over 2023 \* Planned Study + dostarlimab \| 1L NSCLC PDL1high + dostarlimab \| 1L HNSCC PDL1high/low + dostarlimab + CD96 \| Advanced Malignancies + dostarlimab \| 1L NSCLC PDLI high \* Monotherapy/+ iberdomide \| Relapsed Refractory Multiple Myeloma Monotherapy \| High Biomarker + pembrolizumab \| PD-1 Resistant Melanoma + chemotherapy \| Post-IO Chemo-naïve NSCLC Monotherapy \| Advanced Malignancies \* EOS-448: IgG1 antibody targeting TIGIT Inupadenant: Small molecule targeting A2A receptor EOS-984: Small molecule targeting novel mechanism in adenosine pathway + dostarlimab + chemotherapy \| 1L mNSCLC + dostarlimab + PVRIG \| Advanced Malignancies

------

![Slide 7](itos-ex99_1s7.jpg)

EOS-448 / GSK4428859A iTeos and GSK are positioned to leverage the TIGIT/CD226 axis

------

![Slide 8](itos-ex99_1s8.jpg)

Why TIGIT iTeos ideally positioned entering a defining year for TIGIT Validated target in two randomized trials with broad potential. Why EOS-448 Antibody optimized to activate multiple types of immune cells. Why iTeos & GSK $2B collaboration enabling a differentiated and expansive clinical development plan with unique and rational combinations.

------

![Slide 9](itos-ex99_1s9.jpg)

Anti-TIGIT antibody with best-in-class properties and active Fc to induce multiple types of immune response 9 High Potency TIGIT-Binding Domain Functional Fc Domain Maximize activity by leveraging both ends of antibody Antibody design translates to reduction in immunosuppressive cells in patient tumors Antibody design translates into preclinical differentiation Presented at the 2022 AACR Annual Meeting TIGIT+ Tregs (N=31) EOS-448 monotherapy mediates 2- to 4- fold reduction of tumor infiltrating TIGIT+ Tregs cells TIGIT+Tregs cells/mm² Change in BL (%) On-treatment Before treatment

------

![Slide 10](itos-ex99_1s10.jpg)

GSK's PD-1 dostarlimab is the ideal combination partner for EOS-448 PERLA Study (PFS data above): Randomized, double blind phase 2 trial of 1L treatment for metastatic non-squamous NSCLC (N=243) Dostarlimab has proven activity in lung, rectal and endometrial cancers Annals of Oncology (2022) 16 (suppl_1): 100102-100102. Dostarlimab + CT Pembrolizumab + CT Dostarlimab demonstrated compelling efficacy profile in head-to-head trial compared to Pembrolizumab

------

![Slide 11](itos-ex99_1s11.jpg)

First wave of development underway in large indications Clinical strategy: Differentiating to win Leveraging high-quality doublet with dostarlimab in major indications Additional novel doublets beyond PD-1 Unique triplets expanding opportunities \* Planned Study 11 Discovery Preclinical Phase 1 Phase 2 Phase 3 EOS-448: IgG1 antibody targeting TIGIT + dostarlimab \| 1L NSCLC PDL1high + dostarlimab \| 1L HNSCC PDL1high/low + dostarlimab + CD96 \| Advanced Malignancies + dostarlimab \| 1L NSCLC PDLI high \* Monotherapy/+ iberdomide \| Relapsed Refractory Multiple Myeloma + dostarlimab + chemotherapy \| 1L mNSCLC U.S. annual incidence 56 1L NSCLC PD-L1 High Relapsed Refractory MM HNSCC CPS ≥1 K + dostarlimab + PVRIG \| Advanced Malignancies Source: Kantar, iTeos internal analysis

------

![Slide 12](itos-ex99_1s12.jpg)

Adenosine pathway iTeos has developed a unique approach to unlock this important immunosuppressive pathway

------

![Slide 13](itos-ex99_1s13.jpg)

Leveraging unique understanding of adenosine pathway to realize full potential Why Adenosine Pathway Major mechanism of immunosuppression with recent clinical validation. Why Inupadenant Uniquely designed for activity in solid tumors. Why iTeos Deep understanding of the adenosine pathway leading to potential patient selection biomarkers. Identification of new target: First-in-class EOS-984 entering clinic.

------

![Slide 14](itos-ex99_1s14.jpg)

Best-in-Class profile: Inupadenant optimized for activity at high adenosine concentration found in tumors Human primary tumor resections; Adenosine quantified by quantitative mass-spec imaging (QMSI) Low High Adenosine Concentration (µM) Potency (IC50:nM Low High iTeos Arcus Corvus AstraZeneca Novartis Insurmountable, highly selective A2AR antagonist Very high concentrations of adenosine in multiple tumor types iteos Therapeutics internal data

------

![Slide 15](itos-ex99_1s15.jpg)

Clinical activity indicates potential of iTeos-discovered biomarker to guide patient selection RECIST-evaluable patients (N=38) \*Progression-Free >6 Months Biomarker case study Ongoing partial response with inupadenant monotherapy in patient with highest biomarker level observed to date Tumor: Adenocarcinoma of unknown origin Prior progression on three lines: radiation, chemotherapy and PD-1 Target lesion Baseline 1st scan 2nd scan Subcarinal lymph node 15 14 11 Right hilar lymph node 15 15 10 % Reduction 3% 30% Presented at the ASCO 2021 Annual Meeting iteos Therapeutics internal data

------

![Slide 16](itos-ex99_1s16.jpg)

Leveraging our unique knowledge of adenosine pathway with focused investment Clinical strategy: Focused development of inupadenant in post-IO chemo-naïve NSCLC Further evaluation of predictive biomarker First-in-class program (EOS-984) entering clinic \*Planned Study 16 Monotherapy \| High Biomarker + pembrolizumab \| PD-1 Resistant Melanoma + chemotherapy \| Post-IO Chemo-naïve NSCLC Monotherapy \| Advanced Malignancies \* Inupadenant: Small molecule targeting A2A receptor EOS-984: Small molecule targeting a new mechanism in adenosine pathway Discovery Preclinical Phase 1 Phase 2 Phase 3

------

![Slide 17](itos-ex99_1s17.jpg)

iTeos' Mission: We Build Better Drugs Pivotal year for TIGIT EOS-448: Optimized active TIGIT antibody with unique development plans Inupadenant & EOS-984: Designed to exploit the adenosine pathway 2023 Outlook:

------

![Slide 18](itos-ex99_1s18.jpg)

Thank You Nasdaq: ITOS January 2023 18

### Attached PDF Documents

**Attachment 1:** `itos-ex99_1.pdf`

![img-0.jpeg](img-0.jpeg)

# Better Immunotherapies to Improve the Lives of People with Cancer

Nasdaq: ITOS

January 2023

iteostherapeutics.com

# Forward-Looking Statements

![img-1.jpeg](img-1.jpeg)

This presentation contains forward-looking statements. Any statements that are not solely statements of historical fact are forward-looking statements. Words such as 'believe,' 'anticipate,' 'plan,' 'expect,' 'will,' 'may,' 'intend,' 'prepare,' 'look,' 'potential,' 'possible' and similar expressions are intended to identify forward-looking statements. These forward-looking statements include statements relating to the potential benefits of our product candidates and combinations; the potential of TIGIT to be the next advance in cancer treatment; the potential of our biomarker to guide patient selection; our clinical plans and expected timelines, including the expectation to make significant progress in 2023 and that EOS-984 will enter into the clinic in mid-2023; our potential market opportunities; the potential benefits of our collaboration with GSK, including dostarimab being the ideal combination partner for EOS-448; the potential to differentiate EOS-448 to win with the quality of our therapies, major indications and unique combinations; the expectation that 2023 will be a pivotal year for TIGIT and iTeos being ideally positioned to enter this year; and our expected cash runway into 2026.

These forward-looking statements involve risks and uncertainties, many of which are beyond iTeos' control. Actual results could materially differ from those stated or implied by these forward-looking statements as a result of such risks and uncertainties. Known risk factors include the following: success in preclinical testing and early clinical trials does not ensure that later clinical trials will be successful, and early results from a clinical trial do not necessarily predict final results; the data for our product candidates may not be sufficient to support regulatory approval; iTeos may encounter unanticipated costs or may expend cash more rapidly or more slowly than currently anticipated due to challenges and uncertainties inherent in product research and development and biologics manufacturing; the expected benefits and opportunities related to the agreement between iTeos and GSK may not be realized or may take longer to realize than expected due to a variety of reasons, including any inability of the parties to perform their commitments and obligations under the agreement, challenges and uncertainties inherent in product research and development and manufacturing limitations; iTeos may not be able to execute on its business plans, including meeting its expected or planned regulatory milestones and timelines, research and clinical development plans, and bringing its product candidates to market, for various reasons, some of which may be outside of iTeos' control, including possible limitations of company financial and other resources, manufacturing limitations that may not be anticipated or resolved for in a timely manner, regulatory, court or agency decisions such as decisions by the United States Patent and Trademark Office with respect to patents that cover our product candidates and the impact of the COVID-19 pandemic; and those risks identified under the heading 'Risk Factors' in iTeos' Quarterly Report on Form 10-Q for the nine months ended September 30, 2022 filed with the Securities and Exchange Commission (SEC) as well as other SEC filings made by the Company which you are encouraged to review. Statements regarding the Company's cash runway do not indicate when the Company may access the capital markets. Statements regarding the Company's cash runway do not indicate when the Company may access the capital markets.

Any of the foregoing risks could materially and adversely affect iTeos' business, results of operations and the trading price of iTeos' common stock. We caution investors not to place considerable reliance on the forward-looking statements contained in this press release. iTeos does not undertake any obligation to publicly update its forward-looking statements based on events or circumstances after the date hereof.

iteostherapeutics.com

2

![img-2.jpeg](img-2.jpeg)

# Better Immunotherapies to Improve the Lives of People with Cancer

Nasdaq: ITOS

January 2023

iteostherapeutics.com

# iTeos well positioned to deliver better drugs to patients

iTEOS THERAPEUTICS

3

Clinical drug candidates in 2023

11

Clinical studies planned or ongoing

![img-3.jpeg](img-3.jpeg)

$752M*

Cash balance to fund development into 2026

68K

Patients diagnosed each year in US for indications currently in development

$2B

Partnership with unique development possibilities

GSK

10

Years of expertise in tumor immunology

* As of September 30, 2022

iteostherapeutics.com

4

# We build better drugs for people with cancer

iTEOS THERAPEUTICS

![img-4.jpeg](img-4.jpeg)

EOS-448:
Anti-TIGIT optimized for
immune cell activation

Expansive and unique development
plan with GSK

![img-5.jpeg](img-5.jpeg)

Inupadenant & EOS-984:
Designed to fully exploit
the adenosine pathway

Leverage deep understanding of the
adenosine pathway with a focused
clinical plan

iteostherapeutics.com

5

# Expansive and differentiated development pipeline expected to make significant progress over 2023

iTEOS THERAPEUTICS

Discovery

Preclinical

Phase 1

Phase 2

Phase 3

## EOS-448: IgG1 antibody targeting TIGIT

+ dostarlimab | 1L NSCLC PDL1high *

+ dostarlimab | 1L NSCLC PDL1high

+ dostarlimab | 1L HNSCC PDL1high/low

+ dostarlimab + chemotherapy | 1L mNSCLC

+ dostarlimab + CD96 | Advanced Malignancies

+ dostarlimab + PVRIG | Advanced Malignancies

Monotherapy/+ iberdomide | Relapsed Refractory Multiple Myeloma

## Inupadenant: Small molecule targeting A2A receptor

Monotherapy | High Biomarker

+ pembrolizumab | PD-1 Resistant Melanoma

+ chemotherapy | Post-IO Chemo-naïve NSCLC

## EOS-984: Small molecule targeting novel mechanism in adenosine pathway

Monotherapy | Advanced Malignancies *

* Planned Study

iteostherapeutics.com

6

iTEOS THERAPEUTICS

# EOS-448 / GSK4428859A

iTeos and GSK are positioned to leverage the TIGIT/CD226 axis

iteostherapeutics.com

7

# iTeos ideally positioned entering a defining year for TIGIT

iTEOS

THERAPEUTICS

Why
TIGIT

Validated target in two randomized trials with broad potential.

Why
EOS-448

Antibody optimized to activate multiple types of immune cells.

Why
iTeos & GSK

$2B collaboration enabling a differentiated and expansive clinical development plan with unique and rational combinations.

iteostherapeutics.com

8

# Anti-TIGIT antibody with best-in-class properties and active Fc to induce multiple types of immune response

iTEOS

THERAPEUTICS

Maximize activity by leveraging both ends of antibody

![img-6.jpeg](img-6.jpeg)

Antibody design translates into preclinical differentiation

![img-7.jpeg](img-7.jpeg)

Antibody design translates to reduction in immunosuppressive cells in patient tumors

![img-8.jpeg](img-8.jpeg)

Presented at the 2022 AACR Annual Meeting

iteostherapeutics.com

9

# GSK's PD-1 dostarlimab is the ideal combination partner for EOS-448

iTEOS

THERAPEUTICS

Dostarlimab has proven activity in lung, rectal and endometrial cancers

Dostarlimab demonstrated compelling efficacy profile in head-to-head trial compared to Pembrolizumab

![img-9.jpeg](img-9.jpeg)

PERLA Study (PFS data above): Randomized, double blind phase 2 trial of 1L treatment for metastatic non-squamous NSCLC (N=243)

Annals of Oncology (2022) 16 (suppl_1): 100102-100102.

iteostherapeutics.com

10

# First wave of development underway in large indications

iTEOS THERAPEUTICS

## EOS-448: IgG1 antibody targeting TIGIT

![img-0.jpeg](img-0.jpeg)

## U.S. annual incidence

![img-1.jpeg](img-1.jpeg)

Source: Kantar, iTeos internal analysis

## Clinical strategy: Differentiating to win

1. Leveraging high-quality doublet with dostarlimab in major indications
2. Additional novel doublets beyond PD-1
3. Unique triplets expanding opportunities

* Planned Study

iteostherapeutics.com

11

iTEOS THERAPEUTICS

# Adenosine pathway

iTeos has developed a unique approach to unlock this important immunosuppressive pathway

iteostherapeutics.com

12

# Leveraging unique understanding of adenosine pathway to realize full potential

iTEOS THERAPEUTICS

Why Adenosine Pathway

Major mechanism of immunosuppression with recent clinical validation.

Why Inupadenant

Uniquely designed for activity in solid tumors.

Why iTeos

Deep understanding of the adenosine pathway leading to potential patient selection biomarkers.

Identification of new target: First-in-class EOS-984 entering clinic.

iteostherapeutics.com

13

# Best-in-Class profile: Inupadenant optimized for activity at high adenosine concentration found in tumors

iTEOS

THERAPEUTICS

Very high concentrations of adenosine in multiple tumor types

![img-2.jpeg](img-2.jpeg)

Human primary tumor resections: Adenosine quantified by quantitative mass-spec imaging (QMSI)

Insurmountable, highly selective A2aR antagonist

![img-3.jpeg](img-3.jpeg)

iteos Therapeutics internal data

iteostherapeutics.com

14

# Clinical activity indicates potential of iTeos-discovered biomarker to guide patient selection

iTEOS THERAPEUTICS

## RECIST-evaluable patients (N=38)

*Progression-Free >6 Months

![img-4.jpeg](img-4.jpeg)

Presented at the ASCO 2021 Annual Meeting

## Biomarker case study

Ongoing partial response with inupadenant monotherapy in patient with highest biomarker level observed to date

Tumor: Adenocarcinoma of unknown origin

Prior progression on three lines: radiation, chemotherapy and PD-1

| Target lesion | Baseline | 1 st scan | 2 nd scan |
| --- | --- | --- | --- |
| Subcarinal lymph node | 15 | 14 | 11 |
| Right hilar lymph node | 15 | 15 | 10 |
| % Reduction |  | 3% | 30% |

iteos Therapeutics internal data

iteostherapeutics.com

15

# Leveraging our unique knowledge of adenosine pathway with focused investment

iTEOS

THERAPEUTICS

Discovery

Preclinical

Phase 1

Phase 2

Phase 3

## Inupadenant: Small molecule targeting A2a receptor

Monotherapy | High Biomarker

+ pembrolizumab | PD-1 Resistant Melanoma

+ chemotherapy | Post-IO Chemo-naïve NSCLC

## EOS-984: Small molecule targeting a new mechanism in adenosine pathway

Monotherapy | Advanced Malignancies *

### Clinical strategy:

1. Focused development of inupadenant in post-IO chemo-naïve NSCLC
2. Further evaluation of predictive biomarker
3. First-in-class program (EOS-984) entering clinic

*Planned Study

iteostherapeutics.com

16

# iTeos' Mission: We Build Better Drugs

## 2023 Outlook:

- Pivotal year for TIGIT
- EOS-448: Optimized active TIGIT antibody with unique development plans
- Inupadenant & EOS-984: Designed to exploit the adenosine pathway

![img-5.jpeg](img-5.jpeg)

![img-6.jpeg](img-6.jpeg)

![img-7.jpeg](img-7.jpeg)

iteostherapeutics.com

17

ITEOS THERAPEUTICS

# Thank You

Nasdaq: ITOS January 2023

iteostherapeutics.com

18